Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy

David K Packham, Rory St John Wolfe, Anne Therese Reutens, Tomas Berl, Hiddo Lambers Heerspink, Richard Rohde, Sarah E Ivory, Julia B Lewis, Itamar Raz, Thomas B Wiegmann, Juliana C N Chan, Dick de Zeeuw, E J Lewis, Robert Charles Atkins

Research output: Contribution to journalArticleResearchpeer-review

120 Citations (Scopus)


Sulodexide, a mixture of naturally occurring glycosaminoglycan polysaccharide components, has been reported to reduce albuminuria in patients with diabetes, but it is unknown whether it is renoprotective. This study reports the results from the randomized, double-blind, placebo-controlled, sulodexide macroalbuminuria (Sun-MACRO) trial, which evaluated the renoprotective effects of sulodexide in patients with type 2 diabetes, renal impairment, and significant proteinuria (.900 mg/d) already receiving maximal therapy with angiotensin II receptor blockers. The primary end point was a composite of a doubling of baseline serum creatinine, development of ESRD, or serum creatinine 6.0 mg/dl. We planned to enroll 2240 patients over approximately 24 months but terminated the study after enrolling 1248 patients. After 1029 person-years of follow-up, we did not detect any significant differences between sulodexide and placebo; the primary composite end point occurred in 26 and 30 patients in the sulodexide and placebo groups, respectively. Side effect profiles were similar for both groups. In conclusion, these data do not suggest a renoprotective benefit of sulodexide in patients with type 2 diabetes, renal impairment, and macroalbuminuria.
Original languageEnglish
Pages (from-to)123 - 130
Number of pages8
JournalJournal of the American Society of Nephrology
Issue number1
Publication statusPublished - 2012

Cite this